Analysts See $-0.67 EPS for Karyopharm Therapeutics Inc. (KPTI)

April 21, 2018 - By Darrin Black

Investors sentiment decreased to 1.56 in 2017 Q4. Its down 0.94, from 2.5 in 2017Q3. It fall, as 4 investors sold Karyopharm Therapeutics Inc. shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported.
Blackrock invested in 0% or 2.64M shares. Thomas J Herzfeld Advsr Inc reported 1,500 shares or 0.01% of all its holdings. New York State Common Retirement Fund holds 0% or 30,500 shares in its portfolio. First Personal Services invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Point72 Asia (Hong Kong) Limited reported 334 shares stake. Goldman Sachs Grp Inc stated it has 78,107 shares or 0% of all its holdings. Wellington Management Llp has 6.04 million shares for 0.01% of their portfolio. State Board Of Administration Of Florida Retirement System owns 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 14,761 shares. Dimensional Fund Advsr Lp has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Macquarie Gru Ltd has 900 shares for 0% of their portfolio. Fmr Limited Com holds 0% or 3.98M shares in its portfolio. Art Advsr Lc reported 0.01% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Morgan Stanley has 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 69,928 shares. Wells Fargo And Mn invested in 30,974 shares or 0% of the stock. Schwab Charles Invest invested in 0% or 150,289 shares.

Since December 11, 2017, it had 0 insider purchases, and 23 sales for $2.49 million activity. $147,872 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) was sold by Shacham Sharon on Tuesday, February 20. 1,500 Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares with value of $19,500 were sold by Primiano Christopher Brett. 1,500 shares were sold by Mirza Mansoor Raza, worth $19,500 on Wednesday, February 7.

Analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report $-0.67 EPS on May, 3.They anticipate $0.04 EPS change or 5.63 % from last quarter’s $-0.71 EPS. After having $-0.80 EPS previously, Karyopharm Therapeutics Inc.’s analysts see -16.25 % EPS growth. The stock decreased 1.22% or $0.18 during the last trading session, reaching $14.59. About 689,873 shares traded or 53.62% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since April 21, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

Among 6 analysts covering Karyopharm Therapeutics (NASDAQ:KPTI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Karyopharm Therapeutics had 10 analyst reports since November 2, 2017 according to SRatingsIntel. The stock has “Buy” rating by RBC Capital Markets on Thursday, November 2. The stock has “Buy” rating by Canaccord Genuity on Monday, March 12. H.C. Wainwright maintained it with “Buy” rating and $23.0 target in Tuesday, December 12 report. The firm has “Buy” rating by RBC Capital Markets given on Friday, March 2. JP Morgan maintained the shares of KPTI in report on Tuesday, April 10 with “Overweight” rating. The rating was maintained by Jefferies on Friday, March 16 with “Buy”. As per Thursday, March 15, the company rating was maintained by Robert W. Baird. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 15. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Overweight” rating by JP Morgan on Friday, March 16. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, January 11.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $724.43 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: